[Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine].
During a yellow fever vaccination campaign among residents of Rio Branco (Acre State), the frequency of HI antibodies to the most prevalent arboviruses in the Amazon region and to yellow fever virus was determined before and three months after immunization with YF 17D vaccine. From 390 inhabitants included in the first phase of serologic survey (August 1999), only 190 provided a second serum sample, after the use of 17D vaccine (January 2000). Among first phase samples, the frequency of HI antibodies was: 17D (27.2%); Ilheus (5.9%); Mayaro (5.4%); Caraparu (4.9%); Dengue-2 (4.1%); Oropouche (2.3%); and Dengue-1 (0.3%). In the second study phase, the serologic conversion to YF reached 89.7% among previously negative persons. Serologic conversions were also observed to Ilheus (6.2%); Dengue-3 (3.2%); Mayaro (1.1%); and Oropouche (1.1%) viruses. In conclusion, considering the high YF antibody rate after vaccination, the risk of urban yellow fever seems insignificant, although the lower prevalence of HI antibodies to dengue viruses, is of concern and inhabitants are under high risk of dengue outbreaks, especially to DEN-3 recently introduced in Brazil, as was observed in 2000 and 2001 with DEN-1 and DEN-2.
Tavares-Neto
José
J
Faculdade de Medicina, Universidade Federal da Bahia, Uberlândia, MG, Brazil. tavaneto@ufba.br
Freitas-Carvalho
Juliano
J
Nunes
Márcio Roberto Teixeira
MR
Rocha
Grace
G
Rodrigues
Sueli Guerreiro
SG
Damasceno
Edilândio
E
Darub
Recleides
R
Viana
Sebastião
S
Vasconcelos
Pedro Fernando da Costa
PF
D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D001103:Arboviruses / Q000145:classification / Q000276:immunology*; D001938:Brazil / Q000453:epidemiology; D003715:Dengue / Q000453:epidemiology / Q000276:immunology; D003716:Dengue Virus / Q000276:immunology; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D008297:Male; D016036:Seroepidemiologic Studies; D015004:Yellow Fever / Q000453:epidemiology / Q000276:immunology; D022341:Yellow Fever Vaccine / Q000276:immunology*
D000914:Antibodies, Viral; D022341:Yellow Fever Vaccine